Literature DB >> 33353786

Clinical and Contrast-enhanced Ultrasound Characteristics of Epithelioid and Classic Hepatic Angiomyolipoma: Comparison With Alpha-fetoprotein-negative Hepatocellular Carcinoma.

Min-Hong Zou1, Qing Huang2, Qiong Zou3, Ye Jiang4, Jin-Xiu Ju1, Hui-Chao Zhou1, Ju Jiao3, Rong-Qin Zheng5.   

Abstract

Hepatic angiomyolipoma (HAML) comprises epithelioid angiomyolipoma (EAML) and classic hepatic angiomyolipoma (CAML). The imaging appearance of HAML varies widely, and EAML is more easily misdiagnosed as hepatocellular carcinoma (HCC) than as CAML. The clinical and contrast-enhanced ultrasound (CEUS) features of CAML, EAML and HCC with negative alpha-fetoprotein protein expression (HCC[AFP-]) were retrospectively reviewed. The hyper-vascular type was more commonly found in CAML and EAML lesions than in HCC lesions. Most lesions were hyper-enhanced in the arterial phase. CAMLs showed prolonged hyper-enhancement or iso-enhancement during the portal and late phases on CEUS, making them easily distinguishable from HCC(AFP-). Some EAML lesions (41.7%) were hypo-echoic, similar to HCC(AFP-). However, the hypo-enhancement of EAML lesions occurred later than that of HCC(AFP-) lesions. Thus, our findings may be useful in distinguishing among these lesions to improve diagnostic accuracy.
Copyright © 2020 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Hepatic angiomyolipoma; Hepatocellular carcinoma

Year:  2021        PMID: 33353786     DOI: 10.1016/j.ultrasmedbio.2020.11.021

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  1 in total

1.  Diagnostic Value of CEUS LI-RADS Version 2017 in Differentiating AFP-Negative Hepatocellular Carcinoma from Other Primary Malignancies of the Liver.

Authors:  Peihua Wang; Fang Nie; Tiantian Dong; Dan Yang; Ting Liu; Guojuan Wang
Journal:  Diagnostics (Basel)       Date:  2021-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.